Evidence map›Paper›PMID 26419626›Full record

ArticleArthritis research & therapy2015

CD1a+ survivin+ dendritic cell infiltration in dermal lesions of systemic sclerosis.

Sho Mokuda, Tatsuhiko Miyazaki, Yoshifumi Ubara, Masamoto Kanno, Eiji Sugiyama, Kiyoshi Takasugi, Junya Masumoto

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Generation of a novel CD30Clinical and experimental immunology · 2020
    Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Sho MokudaDepartment of Immunology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. sho-mokuda@hiroshima-u.ac.jp.
Tatsuhiko MiyazakiDepartment of Pathology, Ehime University Proteo-Science Centre and Graduate School of Medicine, Shizukawa, Toon, Ehime, 791-0295, Japan. tats_m@gifu-u.ac.jp.
Yoshifumi UbaraNephrology Center and the Okinaka Memorial Institute for Medical Research, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. ubara@toranomon.gr.jp.
Masamoto KannoDepartment of Immunology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. mkanno@hiroshima-u.ac.jp.
Eiji SugiyamaDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. esugiyam@hiroshima-u.ac.jp.
Kiyoshi TakasugiDepartment of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, 21-21 Otsu Dohgo-Himezuka, Matsuyama, Ehime, 790-0858, Japan. keetakas@ehime.med.or.jp.
Junya MasumotoDepartment of Pathology, Ehime University Proteo-Science Centre and Graduate School of Medicine, Shizukawa, Toon, Ehime, 791-0295, Japan. masumoto@m.ehime-u.ac.jp.
Ehime University · JPHiroshima University · JPDogo Onsen Hospital · JPHiroshima University Hospital · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProto-oncogene survivin is a member of the inhibitor of apoptosis (IAP) family of proteins. The presence of serous antibodies against survivin in patients with systemic sclerosis has been previously reported; however, there are few reports regarding the pathophysiological relationship between survivin and systemic sclerosis. We herein investigated the expression and function of survivin in SSc patients.

methodsWe performed immunohistochemistry analyses to determine the expression of XIAP, cIAP and survivin in skin lesions from patients with SSc and non-SSc. The expression levels of survivin in peripheral blood mononuclear cells (PBMCs) obtained from SSc patients and healthy controls were evaluated using RT-PCR and flow cytometry. Additionally, the function of survivin was verified with overexpression experiments using monocyte-derived dendritic cells (Mo-DCs).

resultsThe expression patterns of both XIAP and cIAP were similar, while only the survivin expression differed between the SSc and non-SSc skin lesions. Survivin-overexpressing cells were detected in the SSc dermis frequently. The positive rate of survivin in SSc dermis (64.3%, 9/14) was higher than that in non-SSc dermis (11.2%, 1/9). Furthermore, survivin+ cells expressed CD1a, one of the DC markers. Real-time PCR and FACS analyses revealed that the survivin-WT (wild type) expression levels in PBMCs, in particular CD14+ monocytes, from SSc patients were higher than that from healthy controls. Additionally, the overexpression experiments showed that survivin-WT-overexpressing CD1a+ Mo-DCs have the characteristics of promoting cell cycle progression and decreasing apoptotic cells.

conclusionsThese findings suggest that dermal survivin+ CD1a+ cell infiltration may be a potential biomarker of SSc skin lesions. PBMCs and monocytes from SSc patients also overexpressed survivin; therefore, dermal survivin+ DC may be derived from peripheral blood monocytes. Additionally, survivin may be involved in dermal CD1a+ DC proliferation through cell cycle activation and resistance to apoptosis. Survivin may be an important molecule for the pathogenesis of SSc.

Indexed as

AdultAgedAntigens, CD1Blotting, WesternCells, CulturedDendritic CellsDermisFemaleGene ExpressionHumansImmunohistochemistryInhibitor of Apoptosis ProteinsLeukocytes, MononuclearMaleMicroscopy, ConfocalMiddle AgedAntigens, CD1BIRC5 protein, humanCD1a antigenInhibitor of Apoptosis ProteinsMAS1 protein, humanProto-Oncogene MasSurvivinXIAP protein, humanX-Linked Inhibitor of Apoptosis Protein

Identifiers

PMID26419626
PMCPMC4588499
OpenAlexW2141263462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.